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ABSTRACT
Objectives: Asthmatics have increased risks of
airway-related infections. Little is known about whether
this is true for non-airway-related serious infections
such as Escherichia coli bloodstream infection (BSI).
We assessed whether asthma is associated with a risk
of developing community-acquired E coli BSI.
Design: The study was designed as a population-
based retrospective case–control study.
Setting: This population-based study was conducted
in Olmsted County, Minnesota.
Participants: The study included 259 all eligible
community-acquired E coli BSI cases in Olmsted
County, MN between 1998 and 2007 and 259 birthday-
matched, gender-matched and residency-matched
controls.
Primary and secondary outcome measures: Only
community-acquired E coli BSI cases as the primary
outcome was included. Asthma status as an exposure
was ascertained by predetermined criteria. An adjusted
OR and 95% CI for the association between asthma
and risk of community-acquired E coli BSI was
calculated using conditional logistic regression.
Results: Of 259 eligible cases, 179 (69%) were
women and mean age was 61±22 years. Of the 259
cases 37 (14%) and 16 (6%) of 259 controls had a
prior history of asthma (adjusted OR 2.74; 95% CI
1.11 to 6.76; p=0.029). The population attributable risk
of asthma for community-acquired E coli BSI was 9%.
Although not statistically significant, there was a
borderline association between having a history of food
allergy and increased risk of community-acquired E coli
BSI (6% vs 2%; adjusted OR 3.51; 95% CI 0.94 to
13.11; p=0.062).
Conclusions: Based on the findings of the current
population-based, case–control investigation, a history
of asthma may be associated with risk of community-
acquired E coli BSI. The impact of asthma on risk of
microbial infections may go beyond airways.
INTRODUCTION
Asthma is the most common chronic illness
in childhood and is a major cause of morbid-
ity in adults, affecting 4–17% of children and
7.7% of adults in the USA.1–3 About 300
million people globally are estimated to be
affected by asthma.4
Previous studies showed increased risks of
microbial infections among individuals with
asthma5–10 and the population attributable
risk for asthma of serious pneumococcal
disease was 11–17%.6 10 Impaired innate and
adaptive immune functions among asthmatics
have been suggested for potential underlying
mechanisms.11–18 These study results are
based on microbial infections of the airways.
However, little is known about whether
asthma status is associated with the risk of
non-airway-related bacterial infections such as
community-acquired Escherichia coli blood-
stream infection (BSI).
Addressing this question should provide an
important insight into the nature of the impact
of asthma status on susceptibility to microbial
infection. Specifically, it will improve our
understanding on whether the impact of
asthma status on susceptibility to infection goes
beyond airways. In investigating this question,
community-acquired E coli BSI is suitable
because it is not an airway-related infection but
genitourinary tract/gastrointestinal origin,
E coli is a Gram-negative bacterium with
Toll-like receptor (TLR)-4-mediated signal
transduction for innate immunity and E coli is
ARTICLE SUMMARY
Strengths and limitations of this study
▪ This is the first population-based case–control
study using predetermined criteria for asthma
status and community-acquired Escherichia coli
bloodstream infection. Also, our study setting
has the epidemiologic merits of self-contained
healthcare environment with comprehensive
medical record system for research.
▪ The study has inherent limitations as a retro-
spective study. The study participants were pre-
dominantly white and were a relatively older
population.
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the most common cause of community-acquired BSI.19 Up
to 30% of individuals who developed community-acquired
E coli BSI did not have known risk factors,20 suggesting that
unrecognised risk factors exist that are associated with the
development of community-acquired E coli BSI.
Investigating the relationship between asthma and
non-airway-related serious bacterial infections will advance
our understanding on the extent to which asthma impacts
susceptibility to microbial infections and whether asthma
could be an unrecognised risk factor for non-airway-
related bacterial infections.
We hypothesise that individuals with asthma have an
increased risk of community-acquired E coli BSI, as com-
pared to those without asthma. To test this hypothesis,
we conducted a population-based retrospective case–
control study.
METHODS
This study was designed as a population-based case–
control study.
Study population and setting
Olmsted County, Minnesota is an excellent setting to
conduct a population-based epidemiological study such as
this because medical care is virtually self-contained within
the community (nearly all Olmsted County residents
receive medical care from two medical centres in the com-
munity). The population characteristics of Olmsted
County residents are similar to those of non-Hispanic
white.21 If one grants the authorisation for using medical
record for research (almost 95% of Olmsted County resi-
dents), each patient is assigned a unique identifier under
the auspices of the Rochester Epidemiology Project
(REP).22 Using REP resources, we previously demon-
strated that incidence rates of asthma for this community
are similar to other communities. The annual incidence
rate of asthma in Rochester was 238 cases/100 000
persons, which is comparable to those in other communi-
ties such as Tecumseh, Michigan (250/100 000).23
Study participants: case ascertainment
To test our study hypothesis, we utilised a population-
based incidence parent study, which previously identified
the community-acquired cases to study antimicrobial
resistance trends of E coli BSI in the community.
Details of the case ascertainment have been described
previously.19 Briefly, using the microbiology databases at
Mayo Clinic Rochester and Olmsted Medical Center, all
eligible children and adults with monomicrobial E coli
BSI (n=274) among Olmsted County residents from
1 January 1998 to 31 December 2007 (ie, a population-
based all incident cases of E coli BSI) were identified
based on the criteria suggested by Friedman et al.24
As E coli BSI is required for inpatient parental treatment,
community-acquired E coli BSI was defined by the
isolation of E coli from blood cultures at the time of
hospital admission or within 48 h after hospital
admission for patients who did not fit the criteria for
healthcare-associated infection according to the
Friedman’s criteria.24 Medical records of all participants
were reviewed by investigators of the previous study
(MNA-H) to confirm the diagnosis of community-
acquired E coli BSI, assess clinical features and determine
the eligibility. Only community-acquired E coli BSI was
included because nosocomial and healthcare-associated
E coli BSI are unsuitable to address the aim of the present
study (clinically, they are a high-risk population for E coli
BSI and not representative of the study population). The
index date of BSI was defined as the date when blood cul-
tures that eventually grew E coli were obtained. Exclusion
criteria for cases (and controls) included: (1) polymicro-
bial BSI caused by more than one microorganism, (2)
blood cultures acquired at autopsy, (3) nosocomial and
healthcare-associated E coli BSI, (4) non-Olmsted County
residency at the time of index date of BSI, (5) no
research authorisation for using medical record for
research and (6) health conditions making ascertain-
ment of asthma difficult listed in box 1.
Selection of control participants
Control participants were randomly selected with 1:1
matching from Olmsted County residents who had not
had a history of E coli BSI at the end of the study period.
Briefly, a list of potential control participants who had
received medical care from either Mayo Clinic or
Olmsted Medical Center and who met the matching cri-
teria was generated and randomly selected from the
REP database for the present study. The matching cri-
teria included: (1) gender, (2) birth date (within
6 months for those <18 years of age and within 1 year
for those >18 years of age), (3) the same clinic registra-
tion year as matched case (within 1 year) and (4) closest
clinic visit to index date of matched case within 1 year.
The index date for control participants was defined as
the closest (within 1 year) clinic visit date to index date
of BSI for their corresponding matched case. Based on
the number of cases and controls enroled in this
present study (259 pair), assuming 8% of asthma preva-
lence among controls, this present study had 80% power
to detect an effect size of 2.27 of OR (16.5% of asthma
in cases). This effect size was smaller than the reported
effect sizes for the association between asthma and risk
of microbial infection (OR 2.4–6.7) suggesting adequate
statistical power to address the study aim.6 10
Exposure ascertainment (asthma status)
For determining asthma status of all cases and controls,
we conducted comprehensive medical record reviews to
apply predetermined criteria for asthma as performed
in our previous work.5 6 The criteria are delineated in
box 1. These criteria have been extensively used in
research for asthma epidemiology and were found to
have high reliability.25–30 We included definite as well as
probable asthma according to the criteria prior to the
index date of BSI cases because most probable asthmatics
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become definite over time.6 31 The incidence dates
(the first date when one met the criteria for asthma) for
all patients with asthma were determined; thus, we were
able to discern the temporal relationship between asthma
status (exposure) and E coli BSI (outcome). The risk of E
coli BSI was assessed in relation to the current asthma
status32: remission (no asthma symptoms, no
asthma-related visits or no asthma medications for at least
3 years prior to index date); active or current asthma
(presence of clinical symptoms, asthma-related visits or
asthma medications within 1 year prior to index date)
and inactive (not current) asthma (presence of asthma
symptoms, asthma-related visits or asthma medications
within 1–3 years prior to index date).
Other variables
Pertinent covariates and confounders were collected
from medical records: sociodemographic variables (age,
gender, ethnicity and educational status), asthma medica-
tions including inhaled and systemic corticosteroids,
family history of asthma, atopic status based on sensitisa-
tion against aeroallergens and food allergens, smoking
status (either active or passive exposure to tobacco
smoke), vaccination status and comorbid conditions at
the time of index date as listed in table 1. The period of
data collection was from 1 October 2011 to 30 May 2012.
Statistical analysis
Formal comparison of asthma and other suspected risk
factors between matched cases and controls was per-
formed using conditional logistic regression, with
community-acquired E coli BSI as the target of predic-
tion. All factors were analysed for a univariate association
with BSI and any variables meeting the Greenland entry
criteria (p<0.2) were carried forward into a final multi-
variable model.33 ORs from univariate (unadjusted)
and multivariable (adjusted) models are reported to
express the magnitude of association in terms of the
likelihood of being a case. We calculated the population
attributable risk percentage (PAR%) of asthma for
community-acquired E coli BSI using the formula estab-
lished by Miettinen.34 Statistical significance was tested
at a two-sided α error of 0.05. All analyses were carried
out with the statistical software package SAS, V.9.2 (SAS
Institute, Cary, North Carolina, USA).
RESULTS
Study subjects
Of the 274 patients who were identified in the original
study, 259 were eligible for the present study. Fifteen
patients were excluded: five for consistent FEV1 <50%,
two for restrictive lung disease, two for significant
kyphoscoliosis, two for bronchiectasis, one for cystic
fibrosis, one for pulmonary fibrosis and two due to
non-Olmsted County residency. Of the eligible 259
cases, 179 (69%) were women, 249 (96%) were 18 years
of age or older (age mean±SD, 61±22 years) and 222
(86%) were Caucasian. The characteristics of the cases
and their matched controls, and the individual associa-
tions with community-acquired E coli BSI, are sum-
marised in table 1. There were only 10 asthmatics on
moderate-dose or high-dose inhaled corticosteroid (ICS)
and two asthmatics on systemic corticosteroid at the time
of the index date. Comparing participants with asthma
versus those without, there was no significant difference
in the proportions, who had received influenza vaccine
(40% vs 40%, p=0.99) or 23-valent pneumococcal poly-
saccharide vaccine (PPV23; 49% vs 44%, p=0.49) within
1 year prior to index date.
Association between asthma and risk of
community-acquired E coli BSI
Of the 259 cases, 37 (14%) had a history of asthma
prior to the index date of community-acquired E coli
BSI, compared with 16 of 259 (6%) controls
Box 1 Definition of asthma
Patients were considered to have definite asthma if a physician
had made a diagnosis of asthma with the first two conditions
and/or if each of the following three conditions were present, and
they were considered to have probable asthma if only the first two
conditions were present:
1. History of cough with wheezing, and/or dyspnoea, or history
of cough and/or dyspnoea plus wheezing on examination
2. Substantial variability in symptoms from time to time or
periods of weeks or more when symptoms were absent, and
3. Two or more of the following:
▸ Sleep disturbance by nocturnal cough and wheeze
▸ Non-smoker (14 years or older)
▸ Nasal polyps
▸ Blood eosinophilia higher than 300/μL
▸ Positive wheal and flare skin tests or elevated serum IgE
▸ History of hay fever or infantile eczema or cough, dyspnoea
and wheezing regularly on exposure to an antigen
▸ Pulmonary function tests showing one FEV1 or FVC less
than 70% predicted and another with at least 20% improve-
ment to an FEV1 of higher70% predicted or methacholine
challenge test showing 20% or greater decrease in FEV1
▸ Favorable clinical response to bronchodilator (eg, docu-
mented improvement of respiratory symptoms or FEV1 in
spirometry after bronchodilator therapy)
Patients were excluded from the study if any of these conditions
were present:
▸ Tracheobronchial foreign body at or about the incidence date
▸ Hypogammaglobulinaemia (IgG less than 2.0 mg/mL) or other
immunodeficiency disorder
▸ Wheezing occurring only in response to anaesthesia or
medications
▸ Bullous emphysema or pulmonary fibrosis on chest radiograph
▸ PiZZ α1-antitrypsin
▸ Cystic fibrosis
▸ Other major chest disease such as juvenile kyphoscoliosis or
bronchiectasis FVC forced vital capacity; FEV1, forced expira-
tory volume in 1 s
▸ Pulmonary function tests that showed FEV1 to be consistently
below 50% predicted or diminished diffusion capacity
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(unadjusted OR 2.75; 95% CI 1.42 to 5.32; p=0.003).
Of the 37 case participants with asthma, 33 (89%) had
definite asthma and 4 (11%) had probable asthma. Of
the 16 controls with asthma, 12 (75%) had definite
asthma and 4 (25%) had probable asthma. Among all
53 asthmatics, 18 were on ICS therapy at the index
date (8 on low-dose ICS and 10 on moderate to high-
dose ICS therapy). The effect of asthma on risk of
community-acquired E coli BSI, independent of other
risk factors, is summarised in table 2. Participants with
a history of asthma by predetermined criteria for
asthma in box 1 had a nearly threefold higher risk of
developing community-acquired E coli BSI compared
to those without asthma, controlling for all potential
confounding factors (adjusted OR 2.74; 95% CI 1.11
to 6.76; p=0.029). The PAR% of asthma by predeter-
mined criteria for asthma in box 1 for the risk of
E coli BSI was 9%. The p values for testing a significant
interaction between asthma and categorised age were
as follows: p=0.285 for age cut-off of 65 years (ie, ≥65
vs <65 years), p=0.958 for age cut-off of 40 years (ie,
≥40 vs <40 years) and p=0.417 for age cut-offs of
40 years and 65 years (ie, <40, 40–65, vs >65 years). As
a result, we have no evidence of a differential asthma
effect across age strata. Additional characteristics of
asthma were also evaluated for an association with risk
of community-acquired E coli BSI (see table 3).
Adjusted for other factors, active asthma was associated
with increased risk of E coli BSI but for asthmatics on
ICS therapy compared to non-asthmatics; however, the
Table 1 Sociodemographic and clinical characteristics of patients with Escherichia coli blood stream infection and their
matched control participants
Characteristics Case (n=259) Control (n=259) Unadjusted OR* (95% CI) p Value
Age (years) 61±22 61±22 1.14 (0.78 to 1.67) 0.497
Female gender 179 (69%) 179 (69%) –
Ethnicity <0.001
Caucasian (non-Hispanic) 222 (86%) 245 (95%) Referent
Other 37 (14%) 14 (5%) 4.83 (2.01 to 11.64)
Education status 0.004
Some high school or less 45 (17%) 21 (8%) Referent
High school graduate 95 (37%) 87 (34%) 0.50 (0.27 to 0.93)
Some college or more 110 (42%) 143 (55%) 0.33 (0.18 to 0.62)
Unknown 9 (3%) 8 (3%) –
Influenza vaccination 1 year prior to index date 95 (37%) 110 (42%) 0.75 (0.51 to 1.10) 0.145
PPV23 prior to index date 117 (45%) 114 (44%) 1.08 (0.69 to 1.68) 0.736
Food allergy 16 (6%) 6 (2%) 2.67 (1.04 to 6.81) 0.040
Asthma 37 (14%) 16 (6%) 2.75 (1.42 to 5.32) 0.003
High-risk conditions
Alcohol addiction 17 (7%) 1 (0%) 17.00 (2.26 to 127.75) 0.006
Autoimmune disease‡ 9 (3%) 3 (1%) 3.00 (0.81 to 11.08) 0.099
Chronic obstructive lung disease 12 (5%) 9 (3%) 1.37 (0.55 to 3.42) 0.493
Chronic renal insufficiency 30 (12%) 4 (2%) 9.67 (2.94 to 31.73) <0.001
Congestive heart failure 19 (7%) 2 (1%) 18.00 (2.40 to 134.84) 0.005
Coronary artery disease 52 (20%) 40 (15%) 1.46 (0.89 to 2.41) 0.136
Dementia 16 (6%) 7 (3%) 3.25 (1.06 to 9.97) 0.039
Diabetes mellitus 50 (19%) 24 (9%) 2.53 (1.44 to 4.43) 0.001
History of stroke 15 (6%) 10 (4%) 1.71 (0.67 to 4.35) 0.257
Immobilisation§ 10 (4%) 1 (0%) 10.00 (1.28 to 78.12) 0.028
Immunosuppressive therapy 25 (10%) 4 (2%) 8.00 (2.41 to 26.57) 0.001
Malignancy 21 (8%) 12 (5%) 2.00 (0.90 to 4.45) 0.090
Recurrent urinary tract infection 29 (11%) 2 (1%) 14.50 (3.46 to 60.77) <0.001
Transplant recipients 8 (3%) 0 (0%) –
Urinary incontinence 46 (18%) 20 (8%) 2.86 (1.55 to 5.25) 0.001
Other condition¶ 14 (5%) 0 (0%) – –
Smoke 0.058
No (including ex-smoker) 206 (80%) 222 (86%) Referent
Active 53 (20%) 37 (14%) 1.59 (0.98 to 2.58)
*OR based on matched analysis taking into account gender, birthday, residency and follow-up duration
†Comorbidity conditions are not mutually exclusive.
‡Autoimmune disease includes systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease and other autoimmune
diseases.
§Immobilisation includes hemi/para/quadri-plegia.
¶Other conditions include use of urinary catheter, device, genitourinary procedures (eg, prostate biopsy), and congenital anomaly.
PPV23, 23-valent pneumococcal polysaccharide vaccine.
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overall three-level effect was not statistically significant
(p=0.079).
Other variables and E coli BSI
Several of the high-risk conditions, as well as
non-Caucasian ethnicity, were independently associated
with increased risk of community-acquired E coli BSI
(see tables 1 and 2). A history of food allergy was found
in 16 (6%) of 259 cases as compared with 6 (2%) of 259
controls (adjusted OR 3.51; 95% CI 0.94 to 13.11;
p=0.062). Neither allergic rhinitis (p=0.82) nor atopic
dermatitis (p=0.87) was found to be significantly asso-
ciated with community-acquired E coli BSI.
DISCUSSION
To our knowledge, this is the first population-based, case-
control study that demonstrated an association between
asthma and risk of non-respiratory bacterial infection such
as community-acquired E coli BSI. This association was
Table 2 A multivariable conditional logistic regression model for the association between asthma and risk of
community-acquired Escherichia coli bloodstream infection
Characteristics Case (n=259) Control (n=259) Adjusted OR* (95% CI) p Value
Ethnicity 0.003
Caucasian (non-Hispanic) 222 (86%) 245 (95%) Referent
Other 37 (14%) 14 (5%) 5.90 (1.85 to 18.84)
Education status 0.646
Some high school or less 45 (17%) 21 (8%) Referent
High school graduate 95 (37%) 87 (34%) 0.89 (0.37 to 2.14)
Some college or more 110 (42%) 143 (55%) 0.65 (0.28 to 1.50)
Unknown 9 (3%) 8 (3%) –
Influenza vaccination 1 year prior to index date 95 (37%) 110 (42%) 0.58 (0.33 to 1.02) 0.058
Food allergy 16 (6%) 6 (2%) 3.51 (0.94 to 13.11) 0.062
Asthma 37 (14%) 16 (6%) 2.74 (1.11 to 6.76) 0.029
Active smoking 53 (20%) 37 (14%) 1.31 (0.69 to 2.47) 0.412
High-risk conditions
Alcohol addiction 17 (7%) 1 (0%) 32.31 (1.91 to 546.18) 0.016
Autoimmune diseases 9 (3%) 3 (1%) 1.79 (0.23 to 13.72) 0.574
Chronic renal insufficiency 30 (12%) 4 (2%) 4.76 (1.16 to 19.59) 0.030
Congestive heart failure 19 (7%) 2 (1%) 9.86 (0.93 to 104.59) 0.058
Coronary artery disease 52 (20%) 40 (15%) 0.81 (0.37 to 1.77) 0.593
Dementia 16 (6%) 7 (3%) 4.14 (0.96 to 17.96) 0.057
Diabetes mellitus 50 (19%) 24 (9%) 2.39 (0.97 to 5.87) 0.057
Immobilisation 10 (4%) 1 (0%) 39.86 (2.30 to 690.42) 0.011
Immunosuppressive therapy 25 (10%) 4 (2%) 8.51 (1.32 to 54.96) 0.024
Malignancy 21 (8%) 12 (5%) 2.18 (0.59 to 8.11) 0.243
Recurrent urinary tract infection 29 (11%) 2 (1%) 13.54 (2.42 to 75.65) 0.003
Urinary incontinence 46 (18%) 20 (8%) 2.57 (1.05 to 6.26) 0.038
*Adjusted variables included all variables included in this table.
Table 3 Association of asthma control status and therapy with risk of community-acquired Escherichia coli bloodstream
infection
Asthma characteristics Total (n=518)
Unadjusted OR (95% CI),
p Value
Adjusted OR* (95% CI),
p Value
Inhaled corticosteroid therapy (ICS) p=0.009† p=0.079†
No asthma 465 (90%) Referent Referent
Asthma without ICS 35 (7%) 1.90 (0.88 to 4.09) 1.99 (0.67 to 5.94)
Asthma with ICS 18 (3%) 7.00 (1.59 to 30.80) 5.33 (0.90 to 31.66)
Asthma status‡ p=0.005† p=0.067†
No asthma 465 (90%) Referent Referent
Remission or inactive asthma 17 (3%) 1.25 (0.45 to 3.50) 1.25 (0.25 to 6.30)
Active or current asthma 36 (7%) 4.37 (1.80 to 10.62) 3.89 (1.23 to 12.28)
*Adjusted variables included all factors reported in the multivariable model (see table 2) except for dichotomous asthma status.
†p Value for overall comparison.
‡Active or current asthma was defined as the presence of asthma-related events including asthma symptoms, or use of asthma medications,
and outpatient/emergency department/hospitalisation for asthma within 1 year prior to index date of E coli BSI; remission of asthma was
defined as the absence of asthma-related events >3 years prior to index date; inactive (not current) asthma was defined as the presence of
asthma-related events within 1–3 years prior to index date.
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independent of other risk factors including age, gender,
follow-up duration, ethnicity, educational level and
comorbid conditions (adjusted OR 2.74; 95% CI 1.11
to6.76; p=0.029). Analyses by different age cut-offs showed
that the results were not affected by age (eg, younger vs
older than 40 years of age). Given either the previously
reported non-association (HR 1.29, 95% CI 0.53 to 3.12)
or a protective effect (HR 0.52, 95% CI 0.36 to 0.76) of
ICS therapy on risk of pneumonia in asthmatics35 and a
small number of asthmatics with moderate or high-dose
ICS in our study (10 of 53, 19%), we suspect that active or
current asthma (or collectively those given ICS therapy)
might be related to risk of community-acquired E coli BSI
instead of ICS alone. There were only two patients with
asthma on systemic corticosteroid therapy at the time of
the index date; therefore, exposure to systemic corticoster-
oid therapy was unlikely to account for the observed associ-
ation. We believe that susceptibility bias (eg, covariate
imbalance at baseline) is unlikely to account for the associ-
ation found in our study given the full adjustment for
potential confounders. One concern could be detection
bias stemming from a situation where exposure status
(asthma status) systematically affects detection of out-
comes. However, given that E coli BSI is a life-threatening
condition, this is unlikely and also there was no significant
difference in symptom duration from BSI-related symptom
to index date between asthma and non-asthma in cases
(4.7±5.5 vs 5.2±5.5 days, p=0.61). Since detection of
asthma depends on follow-up duration from registration to
index date of community-acquired E coli BSI, we designed
our study to ensure that duration was similar between
cases and controls. Asthma prevalence in controls in our
study was 6%, which is similar to that in adults (7%) in the
USA (5.5% for men and 9.7% for women).36 Also, the
prevalence of other common chronic conditions such as
coronary heart disease in our study (15%) was similar to
the national average (7.1% for adults aged 45–64 years
and 19.8% for adults aged ≥65 years) suggesting that our
control group may reasonably represent a general popula-
tion of adults in the USA.3 There were no significant dif-
ferences in influenza and PPV23 vaccination rates between
cases and controls, which may imply similar access to
healthcare services. Also, food allergy approached a statis-
tically significant association with the risk of E coli BSI but
other atopic conditions did not. This is probably due to
greater misclassification bias of ascertainment of allergic
rhinitis and atopic dermatitis by International
Classification of Diseases (ICD)-9 code compared to
asthma status and food allergy by predetermined criteria
in our study. Taken together, our study results suggest that
asthma status is independently associated with risk of
community-acquired E coli BSI.
There are only a few previous studies, which assessed
the incidence of E coli BSI and risk factors associated
with its development, including asthma. One study
showed a higher risk of community-acquired E coli BSI
in asthmatics compared to non-asthmatics among those
over 65 years of age (5.5% vs 1%).37 However, another
study showed reduced risk of E coli BSI in asthmatics
(rate ratio: 0.3; 95% CI 0.2 to 0.4) compared to that in
the total regional population.38 These studies have sig-
nificant limitations including no a priori hypothesis
testing on the relationship between asthma and risk of
community-acquired E coli BSI, utilisation of administra-
tive data from healthcare organisations or case reports,
ascertainment of E coli BSI cases and asthma based on
ICD-9 code, inclusion of only elderly patients aged over
65 years37 and no concurrent control group.38 Thus, our
study is the first population-based case–control study
that demonstrated a relationship between asthma and
risk of community-acquired E coli BSI. Several studies
showed increased risks of microbial infections in asth-
matics,5–7 10 11 but these studies only addressed the rela-
tionship between asthma and airway infections.
The mechanisms underlying the apparent association
between asthma and risk of community-acquired E coli
BSI are unknown. Whether previously reported impaired
innate immune factors that may predispose to infections
due to viruses13 39 40 and other bacteria are operative in
community-acquired E coli BSI is undefined. Recently,
Habibzay et al11 reported impaired innate immunity
against pneumococci through impaired TLR-receptor
signal transduction by house dust mite allergic sensitisa-
tion resulting in reduced neutrophil recruitment and
increased risk of pneumococcal infection in the airways.
It is worth investigating whether allergic sensitisation can
induce similar impairment of innate immunity through
TLR-4 for Gram-negative bacteria in genitourinary or
gastrointestinal tracts in asthmatics. Also, an adaptive
immune response to Gram-negative bacteria might be
altered in asthmatics,41 which may affect susceptibility to
Gram-negative bacterial infection. For example, Koch
et al reported impaired type 1 helper T cell (Th1)
response (interleukin-12-induced interferon-γ release
from T lymphocytes) to endotoxin from Salmonella enteri-
tidis in asthmatics.42 Further studies are needed to
address our study findings.
The main strengths of our study are a population-based
study design and include the epidemiological merits of
self-contained healthcare environment with comprehen-
sive medical record system for research. We identified
population-based all incident community-acquired E coli
BSI cases based on the Friedman criteria. We ascertained
asthma status by applying predetermined criteria inde-
pendent of a physician diagnosis of asthma or ICD-9
code. Also, our study has inherent limitations as a retro-
spective study. We could not obtain detailed information
on certain variables such as atopic sensitisation data or
smoking history (eg, duration or the number of cigarettes
a day) but we assumed these data to be missing at
random (ie, it is subject to non-differential misclassifica-
tion bias for comparison groups of interest). Although
our criteria for asthma was based on medical record
review, given the absence of a gold standard for asthma,
the retrospective investigation for feasibility (due to infre-
quent E coli BSI) and the extensive use of the criterion in
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previous asthma research, we believe the criterion is
unlikely to result in a significant bias affecting interpret-
ation of the results. Our study finding that asthma preva-
lence among controls was similar to that at the national
level should mitigate this concern. Our study participants
were predominantly white which might limit generalis-
ability of our results to other ethnic groups. Our study
participants were relatively an older population affected
by many comorbid conditions, which might confound
the study results. Therefore, we adjusted the association
between asthma and risk of E coli BSI for each comorbid
condition individually in our multivariate model. Since
the prevalence of comorbid conditions is related to age,
we examined the effect of the interaction between age
and asthma. We found that the main results on the associ-
ation between asthma and risk of E coli BSI did not
appear to be significantly affected by various cut-offs of
age suggesting the results did not differ by age group
(younger vs older group).
In conclusion, asthmatics might be at an increased risk
of non-respiratory tract bacterial infections, including
community-acquired E coli BSI. The mechanisms respon-
sible for this association are yet to be defined while add-
itional investigations replicate our study findings.
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